Compare Inovio Pharmaceuticals Inc (INO) vs Nuwellis Inc (NUWE) Price & Performance

INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.

The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.

NUWE trades at $1.41, down 0.7% today, with a bearish technical signal despite oversold RSI readings. The company reported a net loss of $17.52 million on $8.27 million revenue in 2025, with negative cash flow from operations. Recent news highlights expansion in pediatric care and a $3.4 million direct offering in July 2026, alongside a reverse stock split executed in June 2026.

Outlook remains challenged by persistent losses and high cash burn, though revenue growth and product development offer potential. Risks include reliance on financing and competitive pressures. Analyst consensus is split evenly between Buy and Hold, reflecting cautious optimism amid fundamental weaknesses.